Parse Biosciences secures $50m in Series C for single cell sequencing


Parse Biosciences has announced a significant milestone in their funding journey, securing a total of $50 million through a Series C equity raise and a debt facility. This round of financing was led by Soleus Capital and witnessed participation from several new and existing investors such as Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital. The debt facility was provided by Horizon Technology Finance Corporation (Nasdaq: HRZN).

This latest financial boost brings Parse Biosciences’ total funding to over $100 million, a significant achievement that positions the company to expand further and scale up to meet the growing demand for its single cell sequencing solutions. This expansion will enable Parse to continue serving its diverse clientele, including academic institutions, biotech companies, and pharmaceutical organizations.

See also  Galecto raises $64m to develop fibrosis and cancer treatments

Parse Biosciences is known for its innovative approach to single cell sequencing, offering a range of products that include Evercode Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and data analysis solutions. These products are designed to enable researchers to perform single cell sequencing with ease and at an unprecedented scale, without the need for custom instrumentation.

Parse Biosciences raises $50m in Series C funding round for single cell sequencing

Parse Biosciences raises $50m in Series C funding round for single cell sequencing

Alex Rosenberg, Ph.D., CEO and co-founder of Parse, highlighted the extraordinary customer response to their products. He emphasized the company’s commitment to supporting large-scale programs in biopharma and making scalable single cell projects routine.

See also  Olema Oncology raises $54m for breast cancer drug candidate OP-1250

David Canner, a partner at Soleus Capital, praised Parse’s unique technology for its role in enabling groundbreaking research and expanding the genomics market. He expressed pride in partnering with Parse as the company grows into a key player in the genomics space.

Gerald A. Michaud, President of Horizon, also acknowledged the transformative impact of Parse’s technology on human health research and treatments. He expressed excitement about supporting Parse as it develops new genomic solutions and expands its operations.

See also  Pyxis Oncology raises $152m in Series B round for cancer therapies

Since its initial launch in 2021, Parse Biosciences’ products have been widely adopted by leading pharmaceutical companies and research universities worldwide. The company has expanded its market reach to several key international regions, including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea. This global expansion underscores the growing influence and potential of Parse Biosciences in the field of genomics and single cell sequencing.

Share This